IPX
ACHAT TOTAL: 663720 titres (~2378393 USD)
- Insiders
- Arima Anastasios, Hannigan Todd
- Total bought
- $2,378,393
- Total sold
- —
- Last activity
- 2026-07-13
- Last synced
-
2026-08-03 21:59:44
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-03
IPX presents a high-conviction, multi-layered catalyst — a $2.38M insider cluster buy post-offering, a critical minerals acquisition, a $6.6M defense titanium award, and a strategic redomiciliation — all converging…
The first sentence of the analysis written for IPX on 2026-08-03 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 6.985 | 13.616 | 7.741 | 2.807 | 2.743 | |
| Quick Ratio | 6.985 | 13.611 | 7.741 | 2.807 | 2.743 | |
| Solvency Ratio | -2.690 | -5.395 | -7.596 | -8.586 | -12.873 | |
| Cash Ratio | 6.503 | 10.866 | 7.246 | 2.727 | 2.665 | |
| Price To Earnings Ratio | -26.250 | -15.180 | -4.860 | -3.625 | -9.374 | |
| Price To Earnings Growth Ratio | -1.313 | 0.455 | 0.778 | -0.032 | -0.003 | |
| Forward Price To Earnings Growth Ratio | -1.313 | 0.455 | 0.778 | -0.032 | -0.003 | |
| Price To Earnings Diluted Ratio | -26.250 | -15.180 | -4.860 | -3.625 | -9.374 | |
| Price To Earnings Diluted Growth Ratio | -1.313 | 0.455 | 0.778 | -0.032 | -0.003 | |
| Price To Book Ratio | 10.037 | 6.441 | 5.957 | 10.522 | 52.807 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -23.548 | -12.396 | -6.596 | -5.553 | -25.641 | |
| Price To Operating Cash Flow Ratio | -42.569 | -17.707 | -7.721 | -6.434 | -26.123 | |
| Debt To Assets Ratio | 0.037 | 0.027 | 0.043 | 0.055 | 0.170 | |
| Debt To Equity Ratio | 0.043 | 0.029 | 0.047 | 0.073 | 0.270 | |
| Debt To Capital Ratio | 0.041 | 0.028 | 0.045 | 0.068 | 0.213 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.001 | 0.004 | 0.183 | |
| Financial Leverage Ratio | 1.136 | 1.080 | 1.109 | 1.335 | 1.586 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -2.586 | -6.120 | -9.629 | -5.834 | -5.585 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.808 | 1.428 | 1.171 | 1.159 | 1.019 | |
| Debt Service Coverage Ratio | -48.586 | -62.216 | -32.814 | -120.373 | -99.539 | |
| Interest Coverage Ratio | -128.453 | 248.481 | -134.789 | -479.847 | -1,079.568 | |
| Short Term Operating Cash Flow Coverage Ratio | -46.180 | -41.896 | -41.462 | -90.386 | -43.870 | |
| Operating Cash Flow Coverage Ratio | -5.540 | -12.528 | -16.266 | -22.345 | -7.480 | |
| Capital Expenditure Coverage Ratio | -1.238 | -2.314 | -5.864 | -6.299 | -53.249 | |
| Dividend Paid And Capex Coverage Ratio | -1.238 | -2.314 | -5.864 | -6.299 | -53.249 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -23.209 | -13.294 | -6.617 | -3.371 | -10.398 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 6.986 | ▼-6.631 | ▲0.207 |
| Quick Ratio | 6.986 | ▼-6.625 | ▲0.208 |
| Solvency Ratio | -2.690 | ▲2.706 | ▲4.738 |
| Cash Ratio | 6.503 | ▼-4.363 | ▲0.502 |
| Price To Earnings Ratio | -26.250 | ▼-11.070 | ▼-14.392 |
| Price To Earnings Growth Ratio | -1.312 | ▼-1.768 | ▼-1.290 |
| Forward Price To Earnings Growth Ratio | -1.312 | ▼-1.768 | ▼-1.290 |
| Price To Earnings Diluted Ratio | -26.250 | ▼-11.070 | ▼-14.392 |
| Price To Earnings Diluted Growth Ratio | -1.312 | ▼-1.768 | ▼-1.290 |
| Price To Book Ratio | 10.037 | ▲3.596 | ▼-7.115 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -23.548 | ▼-11.152 | ▼-8.801 |
| Price To Operating Cash Flow Ratio | -42.569 | ▼-24.862 | ▼-22.458 |
| Debt To Assets Ratio | 0.037 | ▲0.011 | ▼-0.029 |
| Debt To Equity Ratio | 0.043 | ▲0.013 | ▼-0.050 |
| Debt To Capital Ratio | 0.041 | ▲0.013 | ▼-0.038 |
| Long Term Debt To Capital Ratio | 0.000 | ▼-0.000 | ▼-0.038 |
| Financial Leverage Ratio | 1.136 | ▲0.056 | ▼-0.113 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -2.586 | ▲3.534 | ▲3.365 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.808 | ▲0.379 | ▲0.491 |
| Debt Service Coverage Ratio | -48.586 | ▲13.630 | ▲24.120 |
| Interest Coverage Ratio | -128.453 | ▼-376.934 | ▲186.382 |
| Short Term Operating Cash Flow Coverage Ratio | -46.180 | ▼-4.284 | ▲6.579 |
| Operating Cash Flow Coverage Ratio | -5.540 | ▲6.988 | ▲7.292 |
| Capital Expenditure Coverage Ratio | -1.238 | ▲1.076 | ▲12.555 |
| Dividend Paid And Capex Coverage Ratio | -1.238 | ▲1.076 | ▲12.555 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -23.209 | ▼-9.915 | ▼-11.832 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $927.9M | $330.7M | $122.5M | $78.1M | $92.9M | |
| Enterprise value | $877.0M | $299.0M | $111.5M | $72.9M | $91.7M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -40.23x | -16.01x | -7.03x | -6.01x | -25.78x | |
| EV / Free cash flow | -22.26x | -11.21x | -6.01x | -5.19x | -25.30x | |
| EV / EBITDA | -23.21x | -13.29x | -6.62x | -3.37x | -10.40x | |
| Net debt / EBITDA | 1.35x | 1.41x | 0.65x | 0.24x | 0.14x | |
| Current ratio | 6.99x | 13.62x | 7.74x | 2.81x | 2.74x | |
| Income quality | 0.62x | 854.98x | 0.91x | 0.56x | 0.27x | |
| Graham net-net | $1 | $1 | $1 | $0 | $0 | |
| Tax burden | 100.0% | 101.8% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 90.0% | 96.6% | 99.2% | 98.4% | 163.6% | |
| Working capital | $50.4M | $38.5M | $11.1M | $3.8M | $1.1M | |
| Invested capital | $89.2M | $46.3M | $15.1M | $5.1M | $1.6M | |
| Return on assets | -33.7% | -40.1% | -76.5% | -217.2% | -475.7% | |
| Operating ROA | -48.9% | -57.4% | -108.0% | -344.1% | -335.6% | |
| Return on tangible assets | -38.6% | -40.1% | -76.5% | -217.2% | -475.7% | |
| Return on equity | -38.2% | -43.3% | -84.8% | -290.1% | -754.5% | |
| Return on invested capital | -40.5% | -41.4% | -80.6% | -270.1% | -350.4% | |
| Return on capital employed | -40.7% | -42.9% | -83.5% | -279.1% | -376.7% | |
| Earnings yield | -3.8% | -6.7% | -14.2% | -27.6% | -14.3% | |
| Free cash flow yield | -4.2% | -8.1% | -15.2% | -18.0% | -3.9% | |
| Capex / Op. cash flow | -80.8% | -43.2% | -17.1% | -15.9% | -1.9% | |
| Capex / Depreciation | 772.9% | 1244.9% | 634.3% | 1255.6% | 716.6% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 12.9% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 964d | 737d | 409d | 4005d | 11157d | |
| Operating cycle | 0d | 10d | 0d | 0d | 0d | |
| Cash conversion cycle | -964d | -728d | -409d | -4005d | -11157d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+180.6%EV / Sales n/aEV / EBITDA ▼-74.6%EV / Op. cash flow ▼-24.223Earnings yield ▲+0.029
Profitability
Return on equity ▲+0.051Return on assets ▲+0.064Return on invested capital ▲+0.010Return on capital employed ▲+0.022Operating ROA ▲+0.085Income quality ▼-854.361Tax burden ▼-0.018
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+226.440Operating cycle ▼-9.527Cash conversion cycle ▼-235.967Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-6.631Net debt / EBITDA ▼-0.061Working capital ▲+11951231.000Invested capital ▲+42926050.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+898.3%EV / Sales n/aEV / EBITDA ▼-123.2%EV / Op. cash flow ▼-14.455Earnings yield ▲+0.105
Profitability
Return on equity ▲+7.162Return on assets ▲+4.420Return on invested capital ▲+3.099Return on capital employed ▲+3.361Operating ROA ▲+2.866Income quality ▲+0.348Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-10193.608Operating cycle n/aCash conversion cycle ▲+10193.608Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+4.242Net debt / EBITDA ▲+1.208Working capital ▲+49337572.000Invested capital ▲+87546584.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-03 IperionX Advances American Titanium Growth Strategy With Proposed U.S. Redomiciliation and Board Appointment Highlights Proposed U.S. redomiciliation: IperionX intends to redomicile its ultimate parent company to Texas, subject to shareholder, court, regulatory and other customary approvals, to align the Company''s legal and capital-markets structure with its integrated U.S. manufacturing, critical minerals and technology operations. Simplified Nasdaq structure: Subject to final structuring and exchange approvals, common stock in the new U.S. parent is expected to be listed directly on Nasdaq, replacing IperionX''s existing ADS structure.
- 2026-07-31 IperionX Webinar – Investor Update SOUTH BOSTON, Va., July 31, 2026 (GLOBE NEWSWIRE) -- IperionX Limited (NASDAQ: IPX, ASX: IPX) (IperionX) is pleased to invite shareholders and investors to a webinar on Wednesday, August 5, 2026 at 8:00 am Australian Eastern Standard Time / Tuesday, August 4, 2026 at 18:00 pm U.S. Eastern Daylight Time , where Founder and CEO, Taso Arima will provide a company update.
- 2026-07-30 IperionX – June 2026 Quarterly Report SOUTH BOSTON, Va., July 30, 2026 (GLOBE NEWSWIRE) -- IperionX Limited (Nasdaq: IPX | ASX: IPX) is pleased to present its quarterly report for the period ended June 30, 2026.
- 2026-07-26 IperionX (NASDAQ:IPX) Sets New 1-Year Low – Should You Sell? IperionX Limited Sponsored ADR (NASDAQ: IPX - Get Free Report)''s share price reached a new 52-week low on Friday. The company traded as low as $21.60 and last traded at $21.60, with a volume of 2248 shares traded. The stock had previously closed at $21.94. Analyst Upgrades and Downgrades Several brokerages recently weighed in on
- 2026-07-22 IPX1031 Releases Annual List of Top 1031 Exchange Misconceptions for 2026 IPX1031 announces its annual Top 1031 Exchange Misconceptions for 2026, identifying the most common misunderstandings surrounding Tax-Deferred Exchanges.
- 2026-07-07 IperionX Announces Pricing of Public Offering of American Depositary Shares SOUTH BOSTON, Va., July 07, 2026 (GLOBE NEWSWIRE) -- IperionX Limited (“IperionX” or the “Company”) (Nasdaq:IPX; ASX:IPX) today announced the pricing of an underwritten public offering of 2,275,000 of its American Depositary Shares (“ADSs”), with each ADS representing 10 of its ordinary shares (“Public Offering”), at a price per ADS to the public of $21.98, for aggregate gross proceeds of approximately $50 million, before deducting underwriting discounts, commission and estimated offering expenses payable by the Company.
- 2026-07-02 IperionX Completes Strategic Camden Acquisition - Unlocking Ultra-High-Grade Critical Minerals to Accelerate U.S. Supply Chain INVESTMENT HIGHLIGHTS Transformational asset integration & strategic scale: IperionX has successfully completed the acquisition of the Camden critical mineral, heavy rare earths, and infrastructure assets. Highly synergistic with the adjacent Titan Project in Tennessee, this acquisition materially consolidates and expands IperionX''s landholding across the Big Sandy Critical Minerals Province.
- 2026-07-01 IperionX Awarded Up to US$6.6M by OSW-SWIB to Scale U.S. Titanium Plate for Defense Applications IperionX awarded up to US$6.6 million by the Office of the Secretary of War – Submarine Workforce and Industrial Base program (OSW-SWIB) The award forms part of a larger, multi-organization program to scale production of high-performance titanium alloy products, including ballistic-grade titanium plate, for land and maritime defense platforms Funding will support expanded manufacturing capability for large-format military titanium components at IperionX''s Titanium Manufacturing Campus in Virginia, strengthening U.S. capacity for mission-critical titanium products and critical-material supply chains IperionX will collaborate with the George H. W. Bush Combat Development Complex (BCDC) and the U.S. Army Combat Capabilities Development Command (DEVCOM) Army Research Laboratory (ARL) to accelerate product scale-up, validation, and transition pathways for defense and strategic industrial applications Alongside the OSW-SWIB award, IperionX has received an additional purchase order from the U.S. Army Ground Vehicle Systems Center to manufacture a range of titanium fasteners for the JLTV in support of U.S. Army and Marine Corps operational requirements SOUTH BOSTON, Va.
- 2026-06-29 Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson''s Disease and Moderate to Severe Motor Fluctuations MILAN and BRIDGEWATER, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Zambon and Amneal Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson''s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens.
- 2026-06-15 IperionX to Acquire Rights to Rare Earth and Critical Mineral Assets Adjacent to Titan Project SOUTH BOSTON, Va., June 15, 2026 (GLOBE NEWSWIRE) -- IperionX Limited (IperionX) (NASDAQ: IPX, ASX: IPX) is pleased to announce it has entered into an agreement to acquire certain key assets associated with Covia Solutions LLC''s Camden, Tennessee silica sand operation.